Acromegaly Epidemiology

• According to DelveInsight’s analysis, the total prevalent cases of Acromegaly were approximately 59,000 in the 7MM, including the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• Acromegaly is a rare hormonal disorder characterized by excessive production of growth hormone (GH) in the pituitary gland, a small gland located at the base of the brain.
• The disease predominantly affects middle-aged adults, with most patients diagnosed in their 40s to 50s, reflecting the slow, progressive nature of symptom development and frequent delays in clinical recognition.
• Approximately ~95% of acromegaly cases are caused by pituitary adenomas, while a small proportion (~5%) arises from ectopic or non-pituitary sources, highlighting the central role of pituitary pathology in disease epidemiology.
• Despite its rarity, acromegaly is associated with significant underdiagnosis, as clinical features often overlap with common conditions, leading to delays of several years and a higher proportion of patients presenting with established comorbidities at diagnosis.

Acromegaly Epidemiology Forecast in the 7MM

• 2025 Diagnosed Prevalent Cases of Acromegaly: ~59,000
• 2036 Projected Diagnosed Prevalent Cases of Acromegaly: XXXX
• Acromegaly Growth Rate (2026–2036): 0.5% CAGR

DelveInsight's ‘Acromegaly – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the acromegaly, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Acromegaly Understanding and Diagnosis Algorithm

Acromegaly Overview and Diagnosis

Acromegaly is a rare endocrine disorder characterized by chronic overproduction of growth hormone (GH), most commonly caused by a benign pituitary adenoma arising from somatotroph cells. Excess GH leads to elevated insulin-like growth factor 1 (IGF-1) levels, resulting in progressive somatic overgrowth, metabolic dysfunction, and multisystem complications. The disease typically develops insidiously in adults, leading to delayed diagnosis due to gradual symptom progression.

Further details are provided in the report.

Acromegaly Diagnosis

Diagnosis of acromegaly primarily involves biochemical confirmation followed by imaging studies. The initial step includes measurement of serum IGF-1 levels, which serve as a sensitive screening marker. This is followed by a growth hormone suppression test (oral glucose tolerance test, OGTT), where failure of GH suppression confirms the diagnosis. Once biochemical evidence is established, pituitary MRI is performed to localize and characterize the adenoma. Additional evaluation may include assessment of pituitary function and screening for associated comorbidities. Genetic testing may be considered in selected cases, particularly in younger patients or those with a family history suggestive of hereditary syndromes.

Further details are provided in the report.

Acromegaly Epidemiology

Key Findings from Acromegaly Epidemiological Analysis and Forecast 

• According to DelveInsight’s estimates, in 2025, the total number of diagnosed prevalent cases of acromegaly in the 7MM was ~59,000.
• In the United States, acromegaly has an estimated incidence of ~2–11 new cases per million annually, with approximately 20,000–45,000 prevalent cases, though the true burden is likely underestimated due to underdiagnosis. 
• The total diagnosed prevalent cases of acromegaly in the United States were estimated at ~27,500 in 2025, and are projected to increase by 2036, driven by improved detection and greater disease awareness. 
• In the United States, ~95% of cases are attributed to pituitary adenomas, while only ~5% arise from non-pituitary sources, underscoring the dominant role of pituitary-origin disease. 
• Acromegaly demonstrates a slight female predominance (~51% vs. ~49% in males), with most patients diagnosed in their 40s to 50s, reflecting the slow and progressive nature of the disease.
• In EU4 and the UK countries, Germany had the highest number of diagnosed prevalent cases, while Spain had the least.
• Based on tumor size, acromegaly is classified into microadenoma and macroadenoma, which are key determinants of disease severity and treatment strategy.

Scope of the Acromegaly Market Report

• The report covers a segment of a descriptive overview of Acromegaly, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression. 

Acromegaly Market Report Insights

Acromegaly Patient Population Forecast

Acromegaly Market Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by geography)

Discover comprehensive Acromegaly market insights, epidemiology trends, emerging therapies, and forecast opportunities shaping treatment advancements through 2036 globally.

FAQs

• What are the disease risks, burdens, and unmet needs of acromegaly? What will be the growth opportunities across the 7MM concerning the patient population with acromegaly?
• What is the historical and forecasted acromegaly patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy the Acromegaly Market Forecast Report

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives on the diagnostic challenges to overcome barriers in the future.
• Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.